IL-36 alpha/IL-1F6 Antibody (1087K) [Unconjugated]

Recombinant Human IL‑36 alpha /IL‑1F6 protein was serially diluted 2-fold and captured by Rabbit Anti-Human IL‑36 alpha /IL‑1F6 Monoclonal Antibody (Catalog # MAB10783) coated on a Clear Polystyrene Microplate (Catalog # DY990). Rabbit Anti-Human IL‑36 alpha /IL‑1F6 Monoclonal Antibody (Catalog # MAB10782) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998) followed by Substrate Solution (Catalog # DY999) and stopping the enzymatic reaction with Stop Solution (Catalog # DY994).

• Reactivity: Hu
• Applications: ELISA
• Clone: 1087K
• Clonality: Monoclonal
• Host: Rabbit
• Conjugate: Unconjugated

IL-36 alpha/IL-1F6 Antibody (1087K) [Unconjugated] Summary

• Immunogen: E. coli-derived human IL-36 alpha/IL-1F6
  Lys6-Phe158
  Accession # NP_055255
• Specificity: Detects human IL-36 alpha/ IL-1F6 in direct ELISAs.
• Source: N/A
• Isotype: IgG
• Clonality: Monoclonal
• Host: Rabbit
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • ELISA

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for IL-36 alpha/IL-1F6 Antibody (1087K) [Unconjugated]

• FIL1 epsilon
• FIL1
• FIL1(EPSILON)
• FIL1E
• IL-1 epsilon
• IL1(EPSILON)
• IL1E
• IL-1E
• IL-1F6 (FIL-1-epsilon)
• IL1F6
• IL-1F6
• IL36 alpha
• IL-36 alpha
• IL36A
• interleukin 1 family, member 6 (epsilon)
• interleukin 1, epsilon
• Interleukin 36, Alpha
• Interleukin-1 epsilon
• interleukin-1 family member 6
• Interleukin-36 Alpha

Background

Human IL-36 alpha , previously called IL-1F6 and FIL1 epsilon  (family of IL-1 member epsilon), is a member of the IL-1 family which includes IL-1 beta , IL-1 alpha , IL-1ra, IL-18, and novel family members IL-36 Ra (IL-1F5), IL-36 beta (IL-1F8), IL-36 gamma (IL-1F9), IL-37 (IL-1F7) and IL‑38 (IL‑1F10) (1‑4). All family members show a 12  beta ‑strand, beta -trefoil configuration, and are believed to have arisen from a common ancestral gene (1, 2). IL-36 alpha is an 18‑22 kDa, 158 amino acid (aa) intracellular and secreted protein that contains no signal sequence, no prosegment and no potential from N‑linked glycosylation sites (1‑3). It can be released in response to LPS and the cell ATP‑induced activation of the P2X7 receptor (5). A 120 aa isoform missing aa 1‑38 has been reported (6). Human IL‑36 alpha (aa 6 ‑ 158) shares 57‑68% aa sequence identity with mouse, rabbit, equine and bovine IL‑36 alpha and 27‑57% aa sequence identity with other novel IL‑1 family members. IL‑36 alpha is mainly found in skin and lymphoid tissues, but also in fetal brain, trachea, stomach and intestine (1, 3, 7). It is expressed by monocytes, B and T cells (1, 2). The receptor for IL‑36 alpha is a combination of IL‑1 Rrp2 (also called IL1RL2 or IL‑1 R6), mainly found in epithelia and keratinocytes, and the widely expressed IL‑1 RAcP (3, 7). IL-36 alpha , beta , and gamma all activate NF-kappa B and MAPK pathways in an IL‑1 Rrp2 dependent manner, and induce production of inflammatory cytokines and chemokines such as CXCL8/IL-8 (7). IL-36 alpha and other family members are overexpressed in psoriatic skin lesions, and transgenic overexpression of IL‑36 alpha in skin keratinocytes produces epidermal hyperplasia (7‑9). IL-36 alpha is present in kidney tubule epithelia, and it is highly expressed in intubulointerstitial lesions in mouse models of chronic glomerulonephritis, lupus nephritis and diabetic nephritis (10).

1. Smith, D.E. et al. (2000) J. Biol. Chem. 275:1169.
2. Dunn, E. et al. (2001) Trends Immunol. 22:533.
3. Barksby, H.E. et al. (2007) Clin. Exp. Immunol. 149:217.
4. Dinarello, C. et al. (2010) Nat. Immunol. 11:973.
5. Martin, U. et al. (2009) J. Immunol. 183:4021.
6. Entrez Accession # EAW73614.
7. Towne, J.E. et al. (2004) J. Biol. Chem. 279:13677.
8. Blumberg, H. et al. (2010) J. Immunol. 185:4354.
9. Johnston, A. et al. (2011) J. Immunol. 186:2613.
10. Ichii, O. et al. (2010) Lab. Invest. 90:459.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • NP_055255()